Regression of endometriosis following shorter treatment with, or lower dose of danazol. Comparison of pre- and post-treatment laparoscopic findings in the Scandinavian multi-center study

Döberl A, A Döberl, Anton Döberl, Bergqvist A, Agneta Bergqvist, A Bergqvist, Sten Jeppsson, S Jeppsson, Jeppsson S, Aarne I. Koskimies, A I Koskimies, Koskimies AI, Rönnberg L, Lars Rönnberg, L Rönnberg, E Segerbrand, Segerbrand E, Jørgen Starup, Starup J, J Starup
Acta obstetricia et gynecologica Scandinavica. Supplement · 1984 · vol. 63(S123) , pp. 51–58 · doi:10.3109/00016348409156982 · PMID:6238497 · W2127999736
Other OA: closed CC0 ⤵ 16 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study compared danazol treatment regimens for endometriosis, finding that 600 mg daily for 6 months resulted in greater regression than 4 months of 600 mg daily, though dose reduction after 2 months increased irregular bleeding.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

One hundred and sixteen patients with laparoscopically confirmed primary or recurrent endometriosis were treated with danazol, either 600 mg daily for 4 months (group A, n = 76) or 600 mg daily for the first 2 months, followed by 400 mg daily for an additional 4 months (group B, n = 40). The only surgery performed before treatment was biopsies, resection of endometriomas greater than or equal to 3 cm and/or adhesiolysis. The extent of endometriosis before and after treatment was established laparoscopically and recorded by means of a modified AFSrecord as mean additive diameter of implants (mean ADI) in millimeters. This provided a uniform and reproducible quantitative registration for each type and location of endometriotic implant. Both treatment schemes resulted in a highly significant (p less than 0.001) reduction of endometriosis, by 79 and 89% in groups A and B, respectively. However, the reduction in mean ADI was significantly greater (p less than 0.025) in group B which had been treated for a longer period. Moreover, the proportion of patients with extensive pre-treatment lesions (mean ADI greater than or equal to 40 mm) was significantly greater in this group. Active residual endometriosis was found in 21 and 17.5% in groups A and B, respectively. These patients had significantly more extensive endometriosis before treatment. The regression of endometriotic implants was independent of type and/or location, i.e. superficial or scarred; peritoneal, ovarian, or tubal. There was no apparent correlation between the quantitative reduction of endometriosis and amenorrhea versus occasional spotting and/or irregular menstruations.(ABSTRACT TRUNCATED AT 250 WORDS)

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Endometriosis Pregnadienes Adult Adult Amenorrhea Amenorrhea Amenorrhea Danazol Danazol Endometriosis Endometriosis Endometriosis Endometriosis Female Female Humans Humans Laparoscopy Laparoscopy

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (26)

Cited by (16)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:58:08.863946+00:00
unpaywall
last seen: 2026-10-17T06:24:38.187582+00:00
License: CC0 · commercial use OK